Biogen’s CEO Chris Vibacher said ‘a new Biogen’ is emerging following the end of its multiple sclerosis treatments heyday.

US biotech major Biogen (Nasdaq: BIIB) reported stronger-than-expected earnings for the first quarter of 2025, helped by ...

Ionis Pharmaceuticals beat Q1 earnings and revenue estimates, raising its 2025 outlook, and reported strong sales from new and existing drug products.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the "Company") today reported financial results for the first quarter ended March ...

Motor improvements in adults with spinal muscular atrophy (SMA) treated with Spinraza (nusinersen) paralleled a boost in the strength and duration of electrical impulses along nerves that supply the ...

The Russian biotech company Biocad has received a registration certificate for spinal muscular atrophy drug nusinersen, according to the data included in the State Register of Medicines (GRLS). The ...

Management believes its ability to improve motor function over time is superior to its gene therapy rivals and provides supporting data—outperformance over nusinersen—as per the slide below ...

Treatment with Spinraza (nusinersen) and physical therapy that focused on posture improved motor skills in a young boy with spinal muscular atrophy (SMA) type 0 and prevented the progression of ...